Results
Title

CASTLE-HTx.

Authors

Havránek, Štěpán

Abstract

The CASTLE HTx trial showed a significant reduction in the primary composite endpoint in patients with advanced heart failure with reduced ejection fraction and atrial fibrillation who were treated with catheter ablation in addition to optimal medical treatment of heart failure. Catheter ablation was compared with optimal medical treatment alone. The primary endpoint was a composite of death from any cause, implantation of a left ventricular assist device, and urgent heart transplantation.

Subjects

CATHETER ablation; HEART failure; ATRIAL fibrillation; HEART assist devices; HEART failure patients; THERAPEUTICS

Publication

Intervencní a Akutní Kardiologie, 2024, Vol 23, Issue 2/3, p136

ISSN

1213-807X

Publication type

Academic Journal

DOI

10.36290/kar.2024.015